Cargando…

Accumulation of ALDH1-positive cells after neoadjuvant chemotherapy predicts treatment resistance and prognosticates poor outcome in ovarian cancer

Although ovarian cancer is a highly chemosensitive disease, it is only infrequently cured. One of the major reasons lies in the presence of drug-resistant cancer stem-like cells, sufficient to fuel recurrence. We phenotyped cancer stem-like cells by flow cytometry and immunohistochemistry in 55 matc...

Descripción completa

Detalles Bibliográficos
Autores principales: Ayub, Tiyasha H., Keyver-Paik, Mignon-Denise, Debald, Manuel, Rostamzadeh, Babak, Thiesler, Thore, Schröder, Lars, Barchet, Winfried, Abramian, Alina, Kaiser, Christina, Kristiansen, Glen, Kuhn, Walther, Kübler, Kirsten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4599280/
https://www.ncbi.nlm.nih.gov/pubmed/25999351
_version_ 1782394222633025536
author Ayub, Tiyasha H.
Keyver-Paik, Mignon-Denise
Debald, Manuel
Rostamzadeh, Babak
Thiesler, Thore
Schröder, Lars
Barchet, Winfried
Abramian, Alina
Kaiser, Christina
Kristiansen, Glen
Kuhn, Walther
Kübler, Kirsten
author_facet Ayub, Tiyasha H.
Keyver-Paik, Mignon-Denise
Debald, Manuel
Rostamzadeh, Babak
Thiesler, Thore
Schröder, Lars
Barchet, Winfried
Abramian, Alina
Kaiser, Christina
Kristiansen, Glen
Kuhn, Walther
Kübler, Kirsten
author_sort Ayub, Tiyasha H.
collection PubMed
description Although ovarian cancer is a highly chemosensitive disease, it is only infrequently cured. One of the major reasons lies in the presence of drug-resistant cancer stem-like cells, sufficient to fuel recurrence. We phenotyped cancer stem-like cells by flow cytometry and immunohistochemistry in 55 matched samples before and after taxane/platinum-based neoadjuvant chemotherapy. All used markers of stemness (ALDH1, CD24, CD117, CD133) isolated low frequencies of malignant cells. ALDH1 was the most valuable marker for tracking stemness in vivo. The enrichment of ALDH1 expression after treatment was associated with a poor response to chemotherapy, with platinum resistance and independently prognosticated unfavorable outcome. Our results suggest that increased ALDH1 expression after treatment identifies patients with aggressive tumor phenotypes.
format Online
Article
Text
id pubmed-4599280
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-45992802015-10-26 Accumulation of ALDH1-positive cells after neoadjuvant chemotherapy predicts treatment resistance and prognosticates poor outcome in ovarian cancer Ayub, Tiyasha H. Keyver-Paik, Mignon-Denise Debald, Manuel Rostamzadeh, Babak Thiesler, Thore Schröder, Lars Barchet, Winfried Abramian, Alina Kaiser, Christina Kristiansen, Glen Kuhn, Walther Kübler, Kirsten Oncotarget Research Paper Although ovarian cancer is a highly chemosensitive disease, it is only infrequently cured. One of the major reasons lies in the presence of drug-resistant cancer stem-like cells, sufficient to fuel recurrence. We phenotyped cancer stem-like cells by flow cytometry and immunohistochemistry in 55 matched samples before and after taxane/platinum-based neoadjuvant chemotherapy. All used markers of stemness (ALDH1, CD24, CD117, CD133) isolated low frequencies of malignant cells. ALDH1 was the most valuable marker for tracking stemness in vivo. The enrichment of ALDH1 expression after treatment was associated with a poor response to chemotherapy, with platinum resistance and independently prognosticated unfavorable outcome. Our results suggest that increased ALDH1 expression after treatment identifies patients with aggressive tumor phenotypes. Impact Journals LLC 2015-05-11 /pmc/articles/PMC4599280/ /pubmed/25999351 Text en Copyright: © 2015 Ayub et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Ayub, Tiyasha H.
Keyver-Paik, Mignon-Denise
Debald, Manuel
Rostamzadeh, Babak
Thiesler, Thore
Schröder, Lars
Barchet, Winfried
Abramian, Alina
Kaiser, Christina
Kristiansen, Glen
Kuhn, Walther
Kübler, Kirsten
Accumulation of ALDH1-positive cells after neoadjuvant chemotherapy predicts treatment resistance and prognosticates poor outcome in ovarian cancer
title Accumulation of ALDH1-positive cells after neoadjuvant chemotherapy predicts treatment resistance and prognosticates poor outcome in ovarian cancer
title_full Accumulation of ALDH1-positive cells after neoadjuvant chemotherapy predicts treatment resistance and prognosticates poor outcome in ovarian cancer
title_fullStr Accumulation of ALDH1-positive cells after neoadjuvant chemotherapy predicts treatment resistance and prognosticates poor outcome in ovarian cancer
title_full_unstemmed Accumulation of ALDH1-positive cells after neoadjuvant chemotherapy predicts treatment resistance and prognosticates poor outcome in ovarian cancer
title_short Accumulation of ALDH1-positive cells after neoadjuvant chemotherapy predicts treatment resistance and prognosticates poor outcome in ovarian cancer
title_sort accumulation of aldh1-positive cells after neoadjuvant chemotherapy predicts treatment resistance and prognosticates poor outcome in ovarian cancer
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4599280/
https://www.ncbi.nlm.nih.gov/pubmed/25999351
work_keys_str_mv AT ayubtiyashah accumulationofaldh1positivecellsafterneoadjuvantchemotherapypredictstreatmentresistanceandprognosticatespooroutcomeinovariancancer
AT keyverpaikmignondenise accumulationofaldh1positivecellsafterneoadjuvantchemotherapypredictstreatmentresistanceandprognosticatespooroutcomeinovariancancer
AT debaldmanuel accumulationofaldh1positivecellsafterneoadjuvantchemotherapypredictstreatmentresistanceandprognosticatespooroutcomeinovariancancer
AT rostamzadehbabak accumulationofaldh1positivecellsafterneoadjuvantchemotherapypredictstreatmentresistanceandprognosticatespooroutcomeinovariancancer
AT thieslerthore accumulationofaldh1positivecellsafterneoadjuvantchemotherapypredictstreatmentresistanceandprognosticatespooroutcomeinovariancancer
AT schroderlars accumulationofaldh1positivecellsafterneoadjuvantchemotherapypredictstreatmentresistanceandprognosticatespooroutcomeinovariancancer
AT barchetwinfried accumulationofaldh1positivecellsafterneoadjuvantchemotherapypredictstreatmentresistanceandprognosticatespooroutcomeinovariancancer
AT abramianalina accumulationofaldh1positivecellsafterneoadjuvantchemotherapypredictstreatmentresistanceandprognosticatespooroutcomeinovariancancer
AT kaiserchristina accumulationofaldh1positivecellsafterneoadjuvantchemotherapypredictstreatmentresistanceandprognosticatespooroutcomeinovariancancer
AT kristiansenglen accumulationofaldh1positivecellsafterneoadjuvantchemotherapypredictstreatmentresistanceandprognosticatespooroutcomeinovariancancer
AT kuhnwalther accumulationofaldh1positivecellsafterneoadjuvantchemotherapypredictstreatmentresistanceandprognosticatespooroutcomeinovariancancer
AT kublerkirsten accumulationofaldh1positivecellsafterneoadjuvantchemotherapypredictstreatmentresistanceandprognosticatespooroutcomeinovariancancer